AstraZeneca: FDA Issues CRL Regarding SBLA Of Ultomiris In NMOSD

(RTTNews) - AstraZeneca PLC (AZN.L, AZN) said the FDA has issued a complete response letter regarding the supplemental Biologics License Application for long-acting C5 complement inhibitor Ultomiris for the treatment of adult patients with neuromyelitis optica spectrum disorder w https://www.nasdaq.com/articles/astrazeneca:-fda-issues-crl-regarding-sbla-of-ultomiris-in-nmosd